MedTrace Logo

Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer

NCT02036918 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-03-31

No results posted yet for this study

Summary

This study aims to evaluate patients with metastatic castrate-resistant prostate cancer (mCRPC) undergoing treatment with sipuleucel-T for evidence of treatment-associated immune activation in lymph nodes and peripheral blood.

Conditions

Interventions

DRUG

Sipuleucel-T

PROCEDURE

Lymph Node Biopsy

Sponsors & Collaborators

Principal Investigators

  • Brant Inman, MD · Duke University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2019-02-06
Completion
2019-02-06

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02036918 on ClinicalTrials.gov